Philadelphia Health and Education Corporation of Philadelphia has received US Patent No. 8,206,899, "Prostate cancer-related compositions, methods and kits based on DNA microarray proteomics platforms." Methods of detecting and treating prostate cancer are claimed that include modulating or detecting PCADM-1 gene expression and the production and activity of the PCADM-1 polypeptide. Arrays are also claimed for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.